ImageneBio Competitors
| IMA Stock | 7.04 0.05 0.71% |
ImageneBio vs Quince Therapeutics Correlation
Pay attention - limited upside
The correlation between ImageneBio and QNCX is -0.78 (i.e., Pay attention - limited upside) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding ImageneBio and QNCX in the same portfolio, assuming nothing else is changed.
Moving together with ImageneBio Stock
Moving against ImageneBio Stock
| 0.72 | DSGN | Design Therapeutics | PairCorr |
| 0.54 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.47 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.37 | ENGN | enGene Holdings Common | PairCorr |
ImageneBio Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between ImageneBio and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of ImageneBio and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of ImageneBio does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between ImageneBio Stock performing well and ImageneBio Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze ImageneBio's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CNTB | 4.50 | 1.05 | 0.21 | (0.50) | 3.87 | 11.89 | 36.83 | |||
| IFRX | 4.84 | (0.59) | 0.00 | (0.19) | 0.00 | 7.92 | 43.11 | |||
| KLRS | 4.67 | 1.18 | 0.21 | (1.72) | 4.23 | 15.58 | 32.70 | |||
| STTK | 3.53 | 1.14 | 0.34 | 4.22 | 2.84 | 6.42 | 27.07 | |||
| CNTX | 4.15 | 1.27 | 0.29 | 6.76 | 3.46 | 9.59 | 24.11 | |||
| STRO | 4.98 | 0.66 | 0.12 | 0.56 | 5.24 | 11.76 | 27.28 | |||
| ARTV | 6.60 | 0.90 | 0.11 | 0.62 | 7.44 | 8.00 | 118.69 | |||
| OVID | 4.09 | 0.16 | 0.04 | 0.11 | 4.85 | 9.20 | 36.13 | |||
| MGX | 2.98 | (0.69) | 0.00 | (0.31) | 0.00 | 6.02 | 18.63 | |||
| QNCX | 7.63 | (1.00) | 0.00 | (0.35) | 0.00 | 11.88 | 120.72 |
Cross Equities Net Income Analysis
Compare ImageneBio and related stocks such as Connect Biopharma, InflaRx NV, and Kalaris Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CNTB | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (120.3 M) | (205.2 M) | (116.4 M) | (59.5 M) | (15.6 M) | (18 M) | (18.9 M) |
| IFRX | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (8.9 M) | (24.2 M) | (29.8 M) | (59.6 M) | (38.7 M) | (53.9 M) | (31 M) | (42.7 M) | (46.1 M) | (41.5 M) | (43.5 M) |
| KLRS | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (23.8 M) | (69.8 M) | (172 M) | (15.5 M) | (14.7 M) | (58.8 M) | (52.9 M) | (55.5 M) |
| STTK | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (24 M) | (35.4 M) | (45 M) | (100.6 M) | (87.3 M) | (75.4 M) | (67.9 M) | (71.3 M) |
| CNTX | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (24.6 M) | (7.5 M) | (7.5 M) | 6.6 M | (10.5 M) | (14.8 M) | (24 M) | (26.7 M) | (30.7 M) | (32.3 M) |
| STRO | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | (19.7 M) | (35.3 M) | (55.7 M) | (32.1 M) | (105.5 M) | (119.2 M) | (106.8 M) | (227.5 M) | (204.7 M) | (194.5 M) |
| OVID | (447 K) | (447 K) | (447 K) | (447 K) | (447 K) | (13.2 M) | (22.4 M) | (64.8 M) | (52 M) | (59.3 M) | (80.7 M) | 122.8 M | (51.4 M) | (52.3 M) | (26.4 M) | (23.8 M) | (25 M) |
ImageneBio and related stocks such as Connect Biopharma, InflaRx NV, and Kalaris Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in ImageneBio financial statement analysis. It represents the amount of money remaining after all of ImageneBio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.ImageneBio Competitive Analysis
The better you understand ImageneBio competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, ImageneBio's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across ImageneBio's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
ImageneBio Competition Performance Charts
Five steps to successful analysis of ImageneBio Competition
ImageneBio's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by ImageneBio in relation to its competition. ImageneBio's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of ImageneBio in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact ImageneBio's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to ImageneBio, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your ImageneBio position
In addition to having ImageneBio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Latest Losers Thematic Idea Now
Latest Losers
Dynamically computed list of top equities currently sorted across major exchanges. The Latest Losers theme has 262 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Latest Losers Theme or any other thematic opportunities.
| View All Next | Launch |
Check out ImageneBio Correlation with its peers. For information on how to trade ImageneBio Stock refer to our How to Trade ImageneBio Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImageneBio. Market participants price ImageneBio higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive ImageneBio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
ImageneBio's market price often diverges from its book value, the accounting figure shown on ImageneBio's balance sheet. Smart investors calculate ImageneBio's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since ImageneBio's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between ImageneBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImageneBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImageneBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.